← Library
Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Carfilzomib

FDA approved · Rx

Proteasome inhibitor

Also known as: Kyprolis, PR-171, carfilzomibum, PR171, Carfilzomib (PR-171), Carfilzomib (PR171), CAS-868540-17-4

Evidence score
95/ 100
Strong evidence

Strong, human-grade evidence

  • Regulatory standing. FDA-approved prescription medicine
  • Human trials. Backed by controlled human studies
  • Registered human trials. 278 registered studies on ClinicalTrials.gov, most advanced Phase 4
  • 2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Carfilzomib, sold as Kyprolis, is a synthetic tetrapeptide epoxyketone that irreversibly blocks the proteasome, the cell's main system for breaking down unneeded proteins. Blocking it causes damaged and regulatory proteins to build up, which is thought to push cancer cells, especially myeloma cells, toward cell death.

What the evidence shows

Automatic summaryHuman trials

Carfilzomib is FDA approved for treating relapsed or refractory multiple myeloma, alone or in combination with other drugs, and is prescription only. Its human evidence base is large, with 278 registered trials reaching Phase 4 and nearly 1,900 published papers, and it carries known risks including heart, kidney, and blood-related side effects.

Key facts

Molecular formula
C40H57N5O7
Molecular weight
719.9 g/mol
FDA approval
Confirmed on openFDA

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

278registered studies
Phase 4most advanced phase
40completed (sample)
15recruiting (sample)

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1RecruitingNCT06622005

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

Phase 2Active Not RecruitingNCT02773030

Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines

Phase 2CompletedNCT03155100

Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies

RecruitingNCT07051850

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

1,902papers referencing Carfilzomib

Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

N Engl J Med2015

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.

Blood2016

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

Lancet Oncol2016

The role of ubiquitination in tumorigenesis and targeted drug discovery.

Signal Transduct Target Ther2020

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.